Antioxidant and Inhibitory Effect of Scent Leaf (Ocimum gratissimum) on Fe2+ and Sodium Nitroprusside Induced Lipid Peroxidation in Rat Brain In vitro

Neurodegenerative diseases have been linked to oxidative stress arising from peroxidation of membrane biomolecules and high levels of Fe and Sodium nitroprusside have been reported to play an important role in neurodegenerative diseases and other brain disorder. Therefore, this study sought to investigate the inhibitory effect of aqueous, ethanolic and ethyl acetate extract of Ocimum gratissimum leaves on FeSO4 and Sodium Nitroprusside (SNP) induced lipid peroxidation in rat brain in vitro. Incubation of the brain tissue homogenate in the presence of FeSO4 and SNP showed both pro-oxidants [Fe and sodium 2+ nitroprusside (SNP)] caused a significantly reduction in (p<0.05) the accumulation of lipid peroxides in a concentration dependent manner. However, the ethyl acetate fraction significantly (P < 0.05) inhibited Fe2+ induced oxidative stress in the rat brain tissue homogenates than the aqueous and ethanolic extract respectively. This higher inhibitory effect of Ocimum gratissimum could be attributed to its significantly higher phytochemical content, Fe2+ chelating ability, hydroxyl scavenging ability, total phenolic content and reducing power. However, part of the mechanisms through which the extractable phytochemicals in Ocimum gratissimum protect the brain may be through their antioxidant activity, Fe2+ chelating, 1, 1-diphenyl-2-picrylhydrazyl (DPPH) and OH scavenging ability. Therefore, oxidative stress in the brain could be potentially managed/prevented by dietary intake of Ocimum gratissimum

Ameliorative Activity of Ethanol Extract of Artocarpus heterophyllusStem Bark on Pancreaticb-Cell Dysfunction in Alloxan-Induced Diabetic Rats

This study sought to investigate the ameliorative effects of ethanol extractArtocarpus heterophyllus(EAH) in alloxan-induced diabetic rats. The rats were divided into 6 groups, with groups 1 and 2 serving as nondiabetic and diabetic control, respectively; group 3 serving as diabetic rats treated with 5 mg/kg glibenclamide; and groups 4 to 6 were diabetic rats treated with 50, 100, and 150 mg/kg of EAH, respectively. Assays determined were serum insulin, lipid peroxidation, and antioxidant enzyme activities. EAH stem bark reduced fasting blood glucose and lipid peroxidation levels and increased serum insulin levels and activities of antioxidant enzymes. Data obtained demonstrated the ability of EAH stem bark to ameliorate pancreaticb-cell dysfunction in alloxan-induced diabetic rats

The Protective Effect of Polyphenol - Rich Extract of Syzygium cumini Leaves on Cholinesterase and Brain Antioxidant Status in Alloxan - Induced Diabetic Rats

Syzygium cumini leaves are used locally especially in Nigeria for the treatment \ management of diabetes mellitus and Alzheimer’s disease. This study was designed to investigate the effects of polyphenols extracted from Syzygium cumini l eaves on the occurrence of oxidative stress in the brain of rats with diabetes, which can trigger Alzheimer’s disease by determining both in vitro and in vivo c holinesterase, the antioxidant defense system, and the extent of oxidative damage. The effect of polyphenols extracted from Syzygium cumini leaves was investigated on in vitro c holinesterase. Thereafter, the extract (400 mg/kg body weight) of both free and bound polyphenols was administered orally to alloxan - induced rats, and the effect were monitore d on in vivo c holinesterase, superoxide dismutase, catalase, glutathione peroxidase, reduced glutathione, lipid peroxidation and hydroperoxides. The extract demonstrated inhibitory effects against in vitro c holinesterase. A significant reduction in the c ho linesterase activities increased the activities of superoxide dismutase, catalase, glutathione peroxidase, and reduced glutathione. A reduction in lipid peroxidation and hydroperoxide concentrations was observed in the brain of diabetic rats treated with p olyphenols extracted from Syzygium cumini leaves. This study suggests that the polyphenols of Syzygium cumini leaves have anti - Alzheimer and antioxidant boosters, as well as antiperoxidative activities. Therefore, the plant is recommended for both diabetic and Alzheimer’s disease patients worldwid

A standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever

BACKGROUND: Only one recommendation currently exists for the treatment of Lassa fever (LF), which is ribavirin administered in conjunction with supportive care. This recommendation is primarily based on evidence generated from a single clinical trial that was conducted more than 30 years ago-the methodology and results of which have recently come under scrutiny. The requirement for novel therapeutics and reassessment of ribavirin is therefore urgent. However, a significant amount of work now needs to be undertaken to ensure that future trials for LF can be conducted consistently and reliably to facilitate the efficient generation of evidence. METHODOLOGY: We convened a consultation group to establish the position of clinicians and researchers on the core components of future trials. A Core Eligibility Criteria (CEC), Core Case Definition (CCD), Core Outcome Set (COS) and Core Data Variables (CDV) were developed through the process of a multi-stakeholder consultation that took place using a modified-Delphi methodology. RESULTS: A consensus position was achieved for each aspect of the framework, which accounts for the inclusion of pregnant women and children in future LF clinical trials. The framework consists of 8 core criteria, as well as additional considerations for trial protocols. CONCLUSIONS: This project represents the first step towards delineating the clinical development pathway for new Lassa fever therapeutics, following a period of 40 years without advancement. Future planned projects will bolster the work initiated here to continue the advancement of LF clinical research through a regionally-centred, collaborative methodology, with the aim of delineating a clear pathway through which LF clinical trials can progress efficiently and ensure sustainable investments are made in research capacity at a regional level

Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017

A double burden of malnutrition occurs when individuals, household members or communities experience both undernutrition and overweight. Here, we show geospatial estimates of overweight and wasting prevalence among children under 5 years of age in 105 low- and middle-income countries (LMICs) from 2000 to 2017 and aggregate these to policy-relevant administrative units. Wasting decreased overall across LMICs between 2000 and 2017, from 8.4% (62.3 (55.1–70.8) million) to 6.4% (58.3 (47.6–70.7) million), but is predicted to remain above the World Health Organization’s Global Nutrition Target of <5% in over half of LMICs by 2025. Prevalence of overweight increased from 5.2% (30 (22.8–38.5) million) in 2000 to 6.0% (55.5 (44.8–67.9) million) children aged under 5 years in 2017. Areas most affected by double burden of malnutrition were located in Indonesia, Thailand, southeastern China, Botswana, Cameroon and central Nigeria. Our estimates provide a new perspective to researchers, policy makers and public health agencies in their efforts to address this global childhood syndemic

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Background: Future trends in disease burden and drivers of health are of great interest to policy makers and the public at large. This information can be used for policy and long-term health investment, planning, and prioritisation. We have expanded and improved upon previous forecasts produced as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) and provide a reference forecast (the most likely future), and alternative scenarios assessing disease burden trajectories if selected sets of risk factors were eliminated from current levels by 2050. Methods: Using forecasts of major drivers of health such as the Socio-demographic Index (SDI; a composite measure of lag-distributed income per capita, mean years of education, and total fertility under 25 years of age) and the full set of risk factor exposures captured by GBD, we provide cause-specific forecasts of mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) by age and sex from 2022 to 2050 for 204 countries and territories, 21 GBD regions, seven super-regions, and the world. All analyses were done at the cause-specific level so that only risk factors deemed causal by the GBD comparative risk assessment influenced future trajectories of mortality for each disease. Cause-specific mortality was modelled using mixed-effects models with SDI and time as the main covariates, and the combined impact of causal risk factors as an offset in the model. At the all-cause mortality level, we captured unexplained variation by modelling residuals with an autoregressive integrated moving average model with drift attenuation. These all-cause forecasts constrained the cause-specific forecasts at successively deeper levels of the GBD cause hierarchy using cascading mortality models, thus ensuring a robust estimate of cause-specific mortality. For non-fatal measures (eg, low back pain), incidence and prevalence were forecasted from mixed-effects models with SDI as the main covariate, and YLDs were computed from the resulting prevalence forecasts and average disability weights from GBD. Alternative future scenarios were constructed by replacing appropriate reference trajectories for risk factors with hypothetical trajectories of gradual elimination of risk factor exposure from current levels to 2050. The scenarios were constructed from various sets of risk factors: environmental risks (Safer Environment scenario), risks associated with communicable, maternal, neonatal, and nutritional diseases (CMNNs; Improved Childhood Nutrition and Vaccination scenario), risks associated with major non-communicable diseases (NCDs; Improved Behavioural and Metabolic Risks scenario), and the combined effects of these three scenarios. Using the Shared Socioeconomic Pathways climate scenarios SSP2-4.5 as reference and SSP1-1.9 as an optimistic alternative in the Safer Environment scenario, we accounted for climate change impact on health by using the most recent Intergovernmental Panel on Climate Change temperature forecasts and published trajectories of ambient air pollution for the same two scenarios. Life expectancy and healthy life expectancy were computed using standard methods. The forecasting framework includes computing the age-sex-specific future population for each location and separately for each scenario. 95% uncertainty intervals (UIs) for each individual future estimate were derived from the 2·5th and 97·5th percentiles of distributions generated from propagating 500 draws through the multistage computational pipeline. Findings: In the reference scenario forecast, global and super-regional life expectancy increased from 2022 to 2050, but improvement was at a slower pace than in the three decades preceding the COVID-19 pandemic (beginning in 2020). Gains in future life expectancy were forecasted to be greatest in super-regions with comparatively low life expectancies (such as sub-Saharan Africa) compared with super-regions with higher life expectancies (such as the high-income super-region), leading to a trend towards convergence in life expectancy across locations between now and 2050. At the super-region level, forecasted healthy life expectancy patterns were similar to those of life expectancies. Forecasts for the reference scenario found that health will improve in the coming decades, with all-cause age-standardised DALY rates decreasing in every GBD super-region. The total DALY burden measured in counts, however, will increase in every super-region, largely a function of population ageing and growth. We also forecasted that both DALY counts and age-standardised DALY rates will continue to shift from CMNNs to NCDs, with the most pronounced shifts occurring in sub-Saharan Africa (60·1% [95% UI 56·8–63·1] of DALYs were from CMNNs in 2022 compared with 35·8% [31·0–45·0] in 2050) and south Asia (31·7% [29·2–34·1] to 15·5% [13·7–17·5]). This shift is reflected in the leading global causes of DALYs, with the top four causes in 2050 being ischaemic heart disease, stroke, diabetes, and chronic obstructive pulmonary disease, compared with 2022, with ischaemic heart disease, neonatal disorders, stroke, and lower respiratory infections at the top. The global proportion of DALYs due to YLDs likewise increased from 33·8% (27·4–40·3) to 41·1% (33·9–48·1) from 2022 to 2050, demonstrating an important shift in overall disease burden towards morbidity and away from premature death. The largest shift of this kind was forecasted for sub-Saharan Africa, from 20·1% (15·6–25·3) of DALYs due to YLDs in 2022 to 35·6% (26·5–43·0) in 2050. In the assessment of alternative future scenarios, the combined effects of the scenarios (Safer Environment, Improved Childhood Nutrition and Vaccination, and Improved Behavioural and Metabolic Risks scenarios) demonstrated an important decrease in the global burden of DALYs in 2050 of 15·4% (13·5–17·5) compared with the reference scenario, with decreases across super-regions ranging from 10·4% (9·7–11·3) in the high-income super-region to 23·9% (20·7–27·3) in north Africa and the Middle East. The Safer Environment scenario had its largest decrease in sub-Saharan Africa (5·2% [3·5–6·8]), the Improved Behavioural and Metabolic Risks scenario in north Africa and the Middle East (23·2% [20·2–26·5]), and the Improved Nutrition and Vaccination scenario in sub-Saharan Africa (2·0% [–0·6 to 3·6]). Interpretation: Globally, life expectancy and age-standardised disease burden were forecasted to improve between 2022 and 2050, with the majority of the burden continuing to shift from CMNNs to NCDs. That said, continued progress on reducing the CMNN disease burden will be dependent on maintaining investment in and policy emphasis on CMNN disease prevention and treatment. Mostly due to growth and ageing of populations, the number of deaths and DALYs due to all causes combined will generally increase. By constructing alternative future scenarios wherein certain risk exposures are eliminated by 2050, we have shown that opportunities exist to substantially improve health outcomes in the future through concerted efforts to prevent exposure to well established risk factors and to expand access to key health interventions

Effects of Nigella sativa Linn. Oil on Gut Bacteria and Liver Function Status of Albino Wistar Rats

Background: Nigella sativa oil (NSO) has been suggested for use in several food and pharmaceutical applications due to its bioactive contents. Objectives: The present study investigated the effects of 14 µl/g body weight dosage of NSO on body weight, gut microflora and liver function status (LFS) of albino wistar rats. Phytochemical analysis of NSO extract was done. Materials and Methods: Sixty male Wistar rats were randomly assigned into two groups: 14 µl/g body weight of NSO was administered to group A while group B was given an equal volume of distilled water. Five rats provided baseline data for weight, the microbial counts and LFS in a 12-weeks experiment. At two weeks interval, five rats were sacrificed from each group and their intestinal contents were used for the microbial count (Viable, Coliform, E. coli, Staphylococci and Lactic acid bacteria (LAB)) assessment and the blood samples for LFS study. Results: Nigella sativa oil showed the presence of alkaloids (0.083 mg/g), flavonoids (0.302 mg/g), saponins (0.325 mg/g), terpenes (0.138 mg/g), steroids (0.152 mg/g), tannins (0.008 mg/g) and terpenoid (0.138 mg/g). In both groups, the weight of rats continued to increase from the onset of the study, but between 10th and 12th week, non-significant (p&gt;0.05) weight reduction was observed from 191.72±3.23 g to 189.30±4.71 g in the treatment group. Baseline Viable, Coliform, E. coli, Staphylococci and LAB counts (x 106 CFU/g) were 160, 146, 55, 23, and 154 respectively. Sequel to intake of NSO for twelve weeks, the microbial counts (x 106 CFU/g) were respectively 49, 38, 27, 11, and 318. Blood samples also showed a significant (p&lt;0.05) reduction in LFS for Aspartate aminotransferase (78.48 to 60.06U/L), Alanine aminotransferase (30.80 to 18.54 U/L), Alkaline phosphatase (97.00 to 79.34U/L), and Bilirubin (0.52 to 0.20 U/L). Conclusion: Beneficial effects of NSO at the investigated dosage of 14 µl/g body weight has been demonstrated as no toxicological effect was observed

Spilanthes filicaulis (Schumach. & Thonn.) C.D. Adams leaves protects against streptozotocin-induced diabetic nephropathy.

Background and objectiveDiabetic neuropathy (DN) is a complex type of diabetes. The underlying cause of diabetic nephropathy remains unclear and may be due to a variety of pathological conditions resulting in kidney failure. This study examines the protective effect of the methanolic extract of Spilanthes filicaulis leaves (MESFL) in fructose-fed streptozotocin (STZ)-induced diabetic nephropathy and the associated pathway.MethodsTwenty-five rats were equally divided randomly into five categories: Control (C), diabetic control, diabetic + metformin (100 mg/kg), diabetic + MESFL 150 mg/kg bw, and diabetic + MESFL 300 mg/kg bw. After 15 days, the rats were evaluated for fasting blood glucose (FBG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), urea, uric acid, serum creatinine, reduced glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and lipid peroxidation (MDA). Gene expression levels of cyclic adenosine monophosphate (cAMP), protein kinase A (PKA), cAMP response element-binding (CREB), cFOS and the antiapoptotic protein Bcl-2 were examined.ResultsWe observed that MESFL at 150 and 300 mg/kg bw significantly downregulated the protein expression of cAMP, PKA, CREB, and cFOS and upregulated the Bcl-2 gene, suggesting that the nephroprotective action of MESFL is due to the suppression of the cAMP/PKA/CREB/cFOS signaling pathway. In addition, MESFL increases SOD and CAT activities and GSH levels, reduces MDA levels, and reduces renal functional indices (ALP, urea, uric acid, and creatinine).ConclusionTherefore, our results indicate that MESFL alleviates the development of diabetic nephropathy via suppression of the cAMP/PKA/CREB/cFOS pathways